
Tesla Stock Up 7% as Analysts Are Raising Price Target for TSLA Shares
On Friday, Tesla stock closed at $489.61, or 9.66% down. Today, at the time of writing, TSLA stock is 7% up, trading at $524.11.
On Friday, Tesla stock closed at $489.61, or 9.66% down. Today, at the time of writing, TSLA stock is 7% up, trading at $524.11.
Regeneron noted that the initial dose of its COVID-19 drug will be released through a federal government allocation program to approximately 300,000 patients across the country.
The government in Vietnam has threatened to shut down Facebook servers in the country if it does not agree on the new local political content terms.
At the time of writing, Macy’s (M) stock is trading at $8.90 which means that it is 1.06% down.
Zoom shareholders anticipate experiencing a new bull wave after the shares complete the current retracement.
For the past three months, Nvidia reported revenue of $4.73 billion against $4.41 billion expected by analysts.
Nio reported an adjusted net loss of $146.7 million, in the past three months, with total revenues surging 146.4.% year-over-year to $666.6 million.
As CureVac prepares to push its COVID-19 vaccine candidate in the final stage of trials, it is also working on a pan-EU network to manufacture millions of the vaccine doses.
Elon Musk has benefited a lot from the inclusion of Tesla into the S&P 500 index with a positive response from the public.
Moreover, through Berkshire Hathaway Warren Buffett has made a number of other investments in several industries this year besides the pharmaceutical stocks.
Maersk showed good performance in Q3 and recorded a lesser-than-expected revenue fall of 1.4%.
Amazon has launched its Amazon Pharmacy service for the sale of prescription drugs in the US. The products will be delivered free for Amazon Prime members.
Home Depot’s Earnings Per Share came in at $3.18 against the $3.06 expected from analysts. The retailer’s total sales surged by 24% from the year-ago period.
In its full 2020 fiscal year, which ended in September, EasyJet reported £3 billion in revenue.
Pfizer noted that the decision to conduct the vaccine delivery trial was based on the uniqueness of each state because of their size, existing immunization infrastructure, diversity in the population and other factors.